Special oil shows promise for rare brain energy disorder
NCT ID NCT02014883
First seen Oct 31, 2025 · Last updated Jun 21, 2026 · Updated 35 times
Summary
This phase 2 trial tested triheptanoin oil in 20 people with GLUT1 deficiency syndrome, a rare genetic disorder that prevents sugar from fueling the brain. The goal was to see if this special oil could reduce seizures and abnormal movements. Researchers monitored participants for side effects and adjusted doses as needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUT1 DEFICIENCY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brain and Spine Institute
Paris, 75013, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
triheptanoin oil
What this could lead to
If it works, this could provide a new treatment option to reduce seizures and abnormal movements in people with GLUT1 deficiency syndrome.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment may cause side effects like elevated blood levels of certain metabolites, requiring dose adjustments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.